Loading…
Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens
Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady...
Saved in:
Published in: | Bone marrow transplantation (Basingstoke) 2022-02, Vol.57 (2), p.232-242 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Post-transplant cyclophosphamide (PTCy) combined with tacrolimus (TAC) as graft-versus-host disease (GvHD) prophylaxis post-hematopoietic cell transplantation (HCT) is safe and effective. Optimal serum levels of TAC in this combination remain undetermined. We hypothesized that TAC at initial steady state (TISS) of |
---|---|
ISSN: | 0268-3369 1476-5365 |
DOI: | 10.1038/s41409-021-01528-y |